Equities research analysts expect BioTelemetry Inc (NASDAQ:BEAT) to report sales of $103.02 million for the current quarter, Zacks reports. Three analysts have made estimates for BioTelemetry’s earnings. The lowest sales estimate is $101.73 million and the highest is $104.83 million. BioTelemetry reported sales of $91.74 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.3%. The business is expected to issue its next earnings results on Thursday, February 28th.
According to Zacks, analysts expect that BioTelemetry will report full-year sales of $398.90 million for the current year, with estimates ranging from $397.60 million to $400.70 million. For the next fiscal year, analysts forecast that the company will report sales of $439.18 million, with estimates ranging from $437.57 million to $440.60 million. Zacks’ sales averages are an average based on a survey of analysts that follow BioTelemetry.
A number of equities research analysts have recently weighed in on BEAT shares. Raymond James cut their price target on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Wednesday, October 31st. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a report on Saturday, November 3rd. Zacks Investment Research cut BioTelemetry from a “buy” rating to a “hold” rating in a report on Monday, February 4th. ValuEngine raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Sidoti set a $95.00 price target on BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $70.57.
In related news, VP Heather C. Getz sold 8,236 shares of the business’s stock in a transaction that occurred on Thursday, January 17th. The stock was sold at an average price of $70.01, for a total transaction of $576,602.36. Following the sale, the vice president now owns 88,797 shares of the company’s stock, valued at $6,216,677.97. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Heather C. Getz sold 93,383 shares of the business’s stock in a transaction that occurred on Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total value of $6,542,412.98. Following the sale, the vice president now directly owns 119,085 shares in the company, valued at approximately $8,343,095.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 177,198 shares of company stock worth $12,419,736. 8.30% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in the stock. Advisor Group Inc. raised its holdings in BioTelemetry by 256.1% during the fourth quarter. Advisor Group Inc. now owns 25,102 shares of the medical research company’s stock worth $1,498,000 after purchasing an additional 18,053 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioTelemetry during the fourth quarter worth approximately $262,000. Texas Permanent School Fund raised its holdings in BioTelemetry by 5.8% during the fourth quarter. Texas Permanent School Fund now owns 21,793 shares of the medical research company’s stock worth $1,301,000 after purchasing an additional 1,204 shares in the last quarter. Altshuler Shaham Ltd raised its holdings in BioTelemetry by 1,883.8% during the fourth quarter. Altshuler Shaham Ltd now owns 2,321 shares of the medical research company’s stock worth $42,000 after purchasing an additional 2,204 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in BioTelemetry during the fourth quarter worth approximately $2,082,000. 90.54% of the stock is currently owned by hedge funds and other institutional investors.
BioTelemetry Company Profile
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Read More: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.